Holen Sie sich die Stockscreener-App
3.83
0.79%
0.03
Handel nachbörslich:
3.83
Schlusskurs vom Vortag:
$3.80
Offen:
$3.82
24-Stunden-Volumen:
404.47K
Relative Volume:
0.59
Marktkapitalisierung:
$231.41M
Einnahmen:
$40.37M
Nettoeinkommen (Verlust:
$-119.72M
KGV:
-1.8773
EPS:
-2.0402
Netto-Cashflow:
$-135.06M
1W Leistung:
+10.06%
1M Leistung:
+1.06%
6M Leistung:
-4.96%
1J Leistung:
+31.16%
1-Tages-Spanne:
$3.725
$3.85
1-Wochen-Bereich:
$3.41
$3.895
52-Wochen-Spanne:
$2.645
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Firmenname
Voyager Therapeutics Inc
Sektor
Branche
Telefon
857-259-5340
Adresse
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.83 | 229.60M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Eingeleitet | Citigroup | Buy |
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-10-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-26 | Eingeleitet | Guggenheim | Buy |
| 2024-03-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-07 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Eingeleitet | Truist | Buy |
| 2023-03-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-02-03 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-24 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-06 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-15 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-09-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-02-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-11-28 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2017-10-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-23 | Bestätigt | Stifel | Buy |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-28 | Fortgesetzt | Stifel | Buy |
Alle ansehen
Voyager Therapeutics Inc Aktie (VYGR) Neueste Nachrichten
H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
H.C. Wainwright reiterates Voyager Therapeutics stock rating on pipeline progress - Investing.com Australia
Voyager Therapeutics Inc. (VYGR) Q1 2026 Earnings: Narrowed Loss Meets Optimism in Gene Therapy PipelineEPS Consistency Score - Newser
Voyager Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseNet Income Trends - Newser
Voyager Therapeutics (VYGR) Shares Rebound 4.76% as Biotech Sector Shows StrengthCrowd Risk Alerts - Newser
- Insider Monkey
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs - Insider Monkey
Voyager Therapeutics (VYGR) accounting officer reports initial share and option holdings - Stock Titan
The one question every Voyager Therapeutics VYGR investor should ask Bullish Sentiment 20260510High Attention Stocks - Newser
VYGR (NASDAQ: VYGR) affiliate files Form 144 to sell 25,000 shares - Stock Titan
EcoR1 and Oleg Nodelman report 0 shares in Voyager (NASDAQ: VYGR) amendment - Stock Titan
Armistice Capital (VYGR) reports 3.5M shares, 5.87% stake in Voyager - Stock Titan
Voyager Therapeutics (NASDAQ: VYGR) affiliate files to sell 9,406 shares - Stock Titan
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
TradingKey - TradingKey
VYGR Technical Analysis | Trend, Signals & Chart Patterns | VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) - ChartMill
Voyager presents preclinical data for Alzheimer’s gene therapy By Investing.com - Investing.com India
Voyager Therapeutics (VYGR) Reports Positive Findings for Alzhei - GuruFocus
VYGR Secures Mission Management Contract for ISS Research - GuruFocus
Voyager presents preclinical data for Alzheimer’s gene therapy - Investing.com UK
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026 - The Manila Times
Voyager Therapeutics Advances VY1706 Gene Therapy for Alzheimer's Disease with IND Application on Track for Q2 2026 - Quiver Quantitative
Voyager Therapeutics Presents Three-Month GLP Toxicology Data For VY1706 And Provides Updates On Gene Therapy Pipeline - marketscreener.com
CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
The one question every Voyager Therapeutics (VYGR) investor should ask (Bullish Sentiment) 2026-05-10Social Momentum Signals - newser.com
Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes - TipRanks
Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings - TipRanks
Voyager Therapeutics stock (US92916U1025): Q1 2026 results and pipeline updates drive sentiment - AD HOC NEWS
Voyager Therapeutics (VYGR) reports Q1 loss, misses revenue estimates - MSN
Voyager Therapeutics: Q1 Earnings Snapshot - theheraldreview.com
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Alzheimer’s gene therapy moves toward human testing as cash lasts into 2028 - Stock Titan
Voyager Therapeutics (Nasdaq: VYGR) posts Q1 2026 loss and advances tau drugs - Stock Titan
Voyager Therapeutics (Nasdaq: VYGR) trims Q1 2026 loss, holds $171.7M cash - Stock Titan
Voyager Reports First Quarter 2026 Financial and Operating Results - marketscreener.com
VOYAGER THERAPEUTICS, INC. (VYGR) - MSN
Voyager Therapeutics CFO resigns; Robin Swartz takes financial charge - MSN
The key driver behind Voyager Therapeutics (VYGR) revenue growth | Q4 2025: Better Than ExpectedDividend Report - Newser
MSN Money - MSN
Voyager Therapeutics Inc (VYGR) - MSN
Voyager Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR) - The Globe and Mail
Finanzdaten der Voyager Therapeutics Inc-Aktie (VYGR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):